Eve Karloski

Eve Karloski

Auto-generated profile, based on publicly available information

Eve Karloski

Division of Gastroenterology, Hepatology and Nutrition, Department of Medicine, University of Pittsburgh, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 October 2020 in Cancer Prevention Research
Verified
Journal Article
Open access
PDF file
SMSuzanne Patricia MacFarland
Suzanne Patricia MacFarland
JEJessica E. Ebrahimzadeh
Jessica E. Ebrahimzadeh
KZKristin Elizabeth Zelley
Kristin Elizabeth Zelley
LBLubna Begum
Lubna Begum
LBLee M. Bass
Lee M. Bass
BKBryson W Katona
Bryson W Katona
Juvenile polyposis syndrome (JPS) is a clinically diagnosed hamartomatous polyposis syndrome that increases the risk of gastrointestinal cancer. Approximately 40%–50% of JPS is caused by a germline disease-causing variant (DCV) in the SMAD4 or BMPR1A genes. The aim of this study was to characterize the phenotype of DCV-negative JPS and compare it with DCV-positive JPS. Herein, we analyzed a cohort of 145 individuals with JPS from nine institutions, including both pediatric and adult centers. Data analyzed included age at diagnosis, family history, cancer history, need for colectomy/gastrectomy, and polyp number and location. Compared with DCV-positive JPS, DCV-negative JPS was associated with younger age at diagnosis (P < 0.001), lower likelihood of having a family history of JPS (P < 0.001), and a lower risk of colectomy (P = 0.032). None of the DCV-negative individuals had gastric or duodenal polyps, and polyp burden decreased after the first decade compared with DCV-positive JPS. Subgroup analysis between SMAD4 and BMPR1A carriers showed that SMAD4 carriers were more likely to have a family history of JPS and required gastrectomy. Taken together, these data provide the largest phenotypic characterization of individuals with DCV-negative JPS to date, showing that this group has distinct differences compared with JPS due to a SMAD4 or BMPR1A variant. Better understanding of phenotype and cancer risk associated with JPS both with and without a DCV may ultimately allow for individualized management of polyposis and cancer risk. Prevention Relevance: Juvenile Polyposis Syndrome (JPS) is a gastrointestinal cancer predisposition syndrome requiring lifelong surveillance, however there is limited data comparing individuals with and without a germline disease-causing variant in SMAD4 or BMPR1A. Herein we show that individuals with JPS without an underlying disease-causing variant have distinct phenotypic differences including lack of upper gastrointestinal polyps and lower rates of a family history of JPS, suggesting that a different approach to management may be appropriate in this population.

29 May 2024 in Cancer
Verified
Journal Article
Open access
EKEve Karloski
Eve Karloski
BDBeth Dudley
Beth Dudley
BDBrenda Diergaarde
Brenda Diergaarde
ABAmie Blanco
Amie Blanco
JEJessica N. Everett
Jessica N. Everett
RBRandall E. Brand
Randall E. Brand
Background: Pancreatic ductal adenocarcinoma (PDAC) surveillance is recommended for some individuals with a pathogenic or likely pathogenic variant (PV/LPV) in a PDAC susceptibility gene; the recommendation is often dependent on family history of PDAC. This study aimed to describe PDAC family history in individuals with PDAC who underwent genetic testing to determine the appropriateness of including a family history requirement in these recommendations.Methods: Individuals with PDAC with a germline heterozygous PV/LPV in ATM, BRCA1, BRCA2, EPCAM, MLH1, MSH2, MSH6, PALB2, or PMS2 (PV/LPV carriers) were assessed for family history of PDAC in first‐degree relatives (FDRs) or second‐degree relatives (SDRs) from nine institutions. A control group of individuals with PDAC without a germline PV/LPV was also assessed.Results: The study included 196 PV/LPV carriers and 1184 controls. In the PV/LPV carriers, 25.5% had an affected FDR and/or SDR compared to 16.9% in the control group (p = .004). PV/LPV carriers were more likely to have an affected FDR compared to the controls (p = .003) but there was no statistical difference when assessing only affected SDRs (p = .344).Conclusions: Most PV/LPV carriers who developed PDAC did not have a close family history of PDAC and would not have met most current professional societies’ recommendations for consideration of PDAC surveillance before diagnosis. However, PV/LPV carriers were significantly more likely to have a family history of PDAC, particularly an affected FDR. These findings support family history as a risk modifier in PV/LPV carriers, and highlight the need to identify other risk factors.

16 June 2022 in Gastroenterology
Verified
Journal Article
Closed access
MKMarietta Kocher
Marietta Kocher
BDBeth Dudley
Beth Dudley
EKEve Karloski
Eve Karloski
BMBarbara Methe
Barbara Methe
KLKelvin Li
Kelvin Li
RBRandall E. Brand
Randall E. Brand

6 July 2023 in Gastroenterology
Verified
Journal Article
Closed access
NSNadeen Sarsour
Nadeen Sarsour
BDBeth Dudley
Beth Dudley
EKEve Karloski
Eve Karloski
RBRandall E. Brand
Randall E. Brand

22 May 2026 in Pancreatology
Verified
Journal Article
Open access
TSTimothy D. Shu
Timothy D. Shu
LSLynette M Smith
Lynette M Smith
EGErik Gunnarsson
Erik Gunnarsson
APAlessandro Paniccia
Alessandro Paniccia
KLKenneth K. Lee
Kenneth K. Lee
RBRandall E. Brand
Randall E. Brand
Pancreatic ductal adenocarcinoma (PDAC) surveillance is recommended for high-risk individuals (HRI) carrying pathogenic variants (PV) in PDAC susceptibility genes or meeting criteria for familial pancreatic cancer (FPC). Cigarette smoking drives earlier PDAC onset in general populations, but this effect is not well-characterized among HRIs. We hypothesized that smoking accelerates the age at PDAC diagnosis for HRIs. We identified PDAC patients enrolled in the Pancreatic Adenocarcinoma Gene Environment Risk (PAGER) study at the University of Pittsburgh who underwent multi-gene panel testing. Chi-square tests, t-tests, and analysis of variance were used to assess relationships between smoking history and PDAC diagnosis age. Of 3,602 patients with PDAC, 1,266 met eligibility criteria. 148 carried PVs in PDAC susceptibility genes, 154 had FPC, and 964 had sporadic PDAC. Among PV carriers, current smokers were diagnosed 4.1 years earlier than never smokers (P = 0.16). Compared to sporadic patients, PV carriers were diagnosed 1.6 years earlier (P = 0.55) among current smokers, 3.4 years earlier (P = 0.07) among past smokers, and 3.8 years earlier (P = 0.01) among never smokers. PV carriers who had quit smoking more than 10 years prior were diagnosed 9.0 years later than current smokers (P = 0.01) while those who had quit smoking within 10 years had no significant difference in diagnosis age. Cigarette smoking is associated with earlier development of PDAC among PV carriers, but smoking cessation of 10 years or more mitigates this effect. If confirmed in larger studies, these findings suggest smoking history should factor into the age at which PDAC surveillance begins.